Boothbay Fund Management’s Maravai LifeSciences MRVI Stock Holding History

Boothbay Fund Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-55,060	Closed	-$156K	–	2491
2026 Q1	$156K	Buy	+55,060	New	+$187K	﹤0.01%	1821
2021 Q4	–	Sell	-26,300	Closed	-$1.29M	–	2099
2021 Q3	$1.29M	Buy	+26,300	New	+$1.28M	0.04%	638

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Boothbay Fund Management's MRVI Position: Q2 2026 in Review

Boothbay Fund Management sold out of Maravai LifeSciences (MRVI) in Q2 2026, closing a stake of 55,060 shares — an estimated $156K sold.

Boothbay Fund Management first reported a position in MRVI in Q3 2021 and held it in 2 quarters. The position peaked at $1.29M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Boothbay Fund Management reported no remaining Maravai LifeSciences position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 55,060 Maravai LifeSciences shares in Q2 2026, an estimated $156K.
Boothbay Fund Management first reported a position in Maravai LifeSciences in Q3 2021 and held it in 2 quarters.
Boothbay Fund Management's Maravai LifeSciences position peaked at $1.29M in Q3 2021.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.